A Phase 1b, Open-Label, Study of a Novel Targeted Radiotherapy in Children, Adolescents and Young Adults With Inoperable Relapsed or Refractory High-Grade Glioma

The purpose of this dose finding study is to evaluate the safety and efficacy of 2 different dose levels of CLR 131 in children, adolescents and young adults with relapsed or refractory high-grade glioma (HGG).

开始日期2023-10-01

申办/合作机构

Cellectar Biosciences, Inc.

[+1]

NCT04105543

/ Completed临床1期IIT

Therapeutic Combination of CLR 131 With External Beam Radiation in Head and Neck Cancer

This is a Phase 1 study of the use of an investigational drug that selectively delivers radiation to malignant tumor cells, CLR 131, in combination with external beam radiation therapy (EBRT) in subjects with locoregionally recurrent head and neck cancer. The trial will enroll up to 12 participants who are amenable to retreatment with radiation therapy. Participants who also have distant metastatic disease may be enrolled on this clinical trial, but they must have evaluable disease that will be clinically treated with radiation therapy, as per standard of care. All participants will receive a dosimetry test dose of CLR 131 to establish drug uptake by the tumor and enable Monte Carlo dose estimation based on CLR 131 SPECT/CT imaging evaluation. Participants showing uptake will receive a cumulative tumor dose of 60-70 Gy using personalized dose calculation (via Monte Carlo methods) of CLR 131 combined with external beam radiation.

开始日期2019-12-20

申办/合作机构

University of Wisconsin Madison

[+2]

NCT03478462

/ Active, not recruiting临床1期

An Open-Label, Dose Escalation, Efficacy, and Safety Study of CLR 131 in Children, Adolescents, and Young Adults With Select Solid Tumors, Lymphoma, and Malignant Brain Tumors

The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential.

开始日期2019-04-30

申办/合作机构

Cellectar Biosciences, Inc.

100 项与 Iopofosine I-131 相关的临床结果

登录后查看更多信息

100 项与 Iopofosine I-131 相关的转化医学

登录后查看更多信息

100 项与 Iopofosine I-131 相关的专利（医药）

登录后查看更多信息

项与 Iopofosine I-131 相关的文献（医药）

2025-01-01·EBioMedicine

Safety and toxicity of Iopofosine I 131 (CLR 131) with external beam radiation therapy in recurrent or metastatic head and neck cancer: results of a phase 1 single-centre, open-label, single-arm, dose escalation and dose expansion study

Article

作者: Oliver, Kate ; Cho, Steve Y ; Harari, Paul M ; Trask, Diana ; Glazer, Tiffany A ; Kimple, Randall J ; Adam, David P ; Burr, Adam ; Bednarz, Bryan ; Yu, Menggang ; Longcor, Jarrod ; Bruce, Justine Yang ; Rogus-Pulia, Nicole ; McCulloch, Timothy M ; Hill, Patrick ; Piaskowski, Shari M ; Hartig, Gregory K ; Wieland, Aaron M

BACKGROUND:

Re-irradiation of recurrent head and neck cancer (HNC) is often limited by tumour adherence to critical structures and/or radiation tolerance of critical normal tissues. Iopofosine I 131 (CLR 131) is a targeted small molecular phospholipid ether (PLE) drug conjugate that delivers iodine-131 selectively to tumour cells. We conducted a phase 1, single-centre, open-label study to determine whether CLR 131 given with reduced dose of external beam radiation therapy (EBRT) would be tolerable and feasible.

METHODS:

All participants received previous curative intent treatment with radiotherapy as primary or adjuvant treatment. Eligible participants demonstrated uptake of CLR 131 as indicated via single photon emission CT/CT (SPECT/CT) imaging following CLR 131 test dose. Participants received two therapeutic doses of CLR 131 (days 1 and 8) with SPECT/CT imaging performed to quantitate the biodistribution of CLR 131. Participants subsequently received EBRT to achieve the designated radiation dose (60-70 Gy). The primary endpoint was safety. This trial was registered with ClinicalTrials.gov, NCT04105543, and enrolment and follow-up are complete.

FINDINGS:

Twelve participants completed treatment with CLR 131 and EBRT. Eight participants experienced grade 4 non-DLT haematologic toxicities (2 anaemia, 8 leukopenia, 5 thrombocytopenia) at least probably attributed to CLR 131, consistent with the expected toxicity profile. Haematologic toxicities occurred during weeks 6-8 from the first dose of CLR 131 and resolved within three weeks without sequelae. There were no treatment-related grade 3-4 non-haematologic toxicities.

INTERPRETATION:

CLR 131 in combination with EBRT did not confer any safety concerns, and was tolerable in participants with recurrent/metastatic HNC. Myelosuppression was consistent with the known toxicity profile of CLR 131.

FUNDING:

National Institutes of HealthP50 DE026787, National Cancer InstituteP30 CA014520, National Institutes of Health1UL1TR002373, Cellectar, NCT04105543.

2023-09-01·Cancer biotherapy & radiopharmaceuticals

Targeting of Head and Neck Cancer by Radioiodinated CLR1404 in Murine Xenograft Tumor Models with Partial Volume Corrected Theranostic Dosimetry

Article

作者: Adam, David P. ; Grudzinski, Joseph ; Li, Chunrong ; Jeffery, Justin ; Marsh, Ian R. ; Longhurst, Colin ; Hernandez, Reinier ; Bednarz, Bryan P. ; Harari, Paul M. ; Weichert, Jamey P.

Background: Delivery of radiotherapeutic dose to recurrent head and neck cancer (HNC) is primarily limited by locoregional toxicity in conventional radiotherapy. As such, HNC patients stand to benefit from the conformal targeting of primary and remnant disease achievable with radiopharmaceutical therapies. In this study, the authors investigated the tumor targeting capacity of ¹³¹I-CLR1404 (iopofosine I-131) in various HNC xenograft mouse models and the impact of partial volume correction (PVC) on theranostic dosimetry based on ¹²⁴I-CLR1404 (CLR 124) positron emission tomography (PET)/computed tomography (CT) imaging. Methods: Mice bearing flank tumor xenograft models of HNC (six murine cell line and six human patient derived) were intravenously administered 6.5-9.1 MBq of CLR 124 and imaged five times over the course of 6 d using microPET/CT. In vivo tumor uptake of CLR 124 was assessed and PVC for ¹²⁴I was applied using a novel preclinical phantom. Using subject-specific theranostic dosimetry estimations for iopofosine I-131 based on CLR 124 imaging, a discrete radiation dose escalation study (2, 4, 6, and 8 Gy) was performed to evaluate tumor growth response to iopofosine I-131 relative to a single fraction of external beam radiation therapy (6 Gy). Results: PET imaging demonstrated consistent tumor selective uptake and retention of CLR 124 across all HNC xenograft models. Peak uptake of 4.4% ± 0.8% and 4.2% ± 0.4% was observed in squamous cell carcinoma-22B and UW-13, respectively. PVC application increased uptake measures by 47%-188% and reduced absolute differences between in vivo and ex vivo uptake measurements from 3.3% to 1.0 percent injected activity per gram. Tumor dosimetry averaged over all HNC models was 0.85 ± 0.27 Gy/MBq (1.58 ± 0.46 Gy/MBq with PVC). Therapeutic iopofosine I-131 studies demonstrated a variable, but linear relationship between iopofosine I-131 radiation dose and tumor growth delay (p < 0.05). Conclusions: Iopofosine I-131 demonstrated tumoricidal capacity in preclinical HNC tumor models and the theranostic pairing with CLR 124 presents a promising new treatment approach for personalizing administration of iopofosine I-131.

2022-02-01·PEDIATRIC PULMONOLOGY

Does recorded oximetry utilizing a consensus‐based algorithm compare to polysomnography in discontinuing home oxygen therapy in premature infants?

Article

作者: Sobelman, Celia ; Lee, Austin ; White, Heather ; Rhein, Lawrence M. ; Kremer, Ted

Abstract:

Background:

Approximately a third of all extremely preterm infants diagnosed with bronchopulmonary dysplasia will require home oxygen therapy (HOT). Lack of consensus‐based guidelines has led to significant variability in outpatient HOT management in the United States. A common assessment performed before discontinuing oxygen is a formal polysomnogram (PSG). PSGs are potentially undesirable due to cost, lack of convenient access, and parental stress, so alternative testing to determine the optimal timing of safe oxygen discontinuation are needed.

Methods:

We compared nocturnal recorded home oximetry (RHO) with PSG data in a cohort of patients from the RHO trial for patients who had recordings performed simultaneously to or within 24 h of their PSG. The RHO trial was a randomized, unblinded, multi‐center trial comparing two oxygen management strategies. Parameters of oxygenation were compared between PSG and RHO, and nonoximegtry findings from the PSG that changed clinical management were identified.

Results:

A total of 53 infants randomized to obtain a PSG as part of the RHO trial (55%) completed a PSG, and of those, 32 (64%) completed both a PSG with comparison RHO. There were more white infants in both groups than other races and ethnicities. Bland–Altman analysis showed a strong agreement of oxygen saturation time below 90% SpO2 between PSG and RHO results (slope = 1.014, p = 0.24). Results agreed in 96% of cases.

Conclusion:

RHO is a safe and effective alternative to PSG to assist in determination of discontinuing HOT in infants with BPD without other risks for sleep‐disordered breathing.

项与 Iopofosine I-131 相关的新闻（医药）

2025-06-05

·GlobeNewswire-Health Care

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules

FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the entry into definitive agreements to raise $2.5 million from the sale of shares of the company’s common stock priced at-market for Nasdaq purposes. The closing of the offering is expected to occur on or about June 6, 2025, subject to satisfaction of customary closing conditions. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the offering. The agreements provide for the immediate exercise of certain outstanding warrants to purchase an aggregate of 8,301,322 shares of common stock, issued by the company on June 5, 2020, October 25, 2022 and July 21, 2024 (the “Existing Warrants”), at a reduced exercise price of $0.3041 per share. The shares of common stock issuable upon exercise of the Existing Warrants are all registered, or their resale is registered, pursuant to effective registration statements. The company did not issue any replacement warrants. The gross proceeds to the company from the exercise of the Existing Warrants are expected to be approximately $2.5 million, prior to deducting placement agent fees and offering expenses. The company intends to use the net proceeds for general corporate purposes, including working capital and operating expenses. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Cellectar Biosciences, Inc. Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s product pipeline includes: iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope), for which the FDA has granted Breakthrough Therapy Designation; CLR 121225, an actinium-225 based program being targeted to several solid tumors with significant unmet need, such as pancreatic cancer; and CLR 121125, an iodine-125 Auger-emitting program targeted in other solid tumors, such as triple negative breast, lung and colorectal, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. In addition, iopofosine I 131 has been studied in Phase 2b trials for relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma, and the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has also granted iopofosine I 131 six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications. For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: X, LinkedIn, and Facebook. Forward-Looking Statement Disclaimer This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to identify suitable collaborators, partners, licensees or purchasers for our product candidates and, if we are able to do so, to enter into binding agreements with regard to any of the foregoing, or to raise additional capital to support our operations, or our ability to fund our operations if we are unsuccessful with any of the foregoing. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2024, and our Form 10-Q for the quarter ended March 31, 2025. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements. Contacts INVESTORS:Anne Marie FieldsPrecision AQ212-362-1200annemarie.fields@precisionaq.com

孤儿药快速通道临床2期突破性疗法

2025-06-04

·药明康德

首款！拜耳小分子联合疗法再获FDA批准；总缓解率超80%！潜在“first-in-class”疗法获FDA突破性疗法认定……

达3期试验所有主要与次要终点！小分子疗法积极结果公布Sagimet Biosciences今日宣布，其口服脂肪酸合酶（FASN）抑制剂denifanstat在3期临床试验中达到所有主要与次要终点。此外，Sagimet近期已在美国启动第二款FASN抑制剂TVB-3567的1期临床研究，计划未来用于治疗痤疮。该3期研究为随机、双盲、安慰剂对照、多中心临床试验，共纳入480名中重度痤疮患者，按1：1随机接受每日一次50 mg denifanstat或安慰剂治疗，持续12周。该试验由Sagimet的合作伙伴歌礼制药（Ascletis Bioscience）主导，旨在评估denifanstat治疗中重度寻常型痤疮的安全性与有效性。研究的主要终点包括治疗成功率，即研究者总体评估（IGA）评分为0/1（皮肤症状清除或几乎清除，且较基线下降至少2分）、总皮损计数变化百分比及炎性皮损计数变化百分比。结果显示，denifanstat在所有主要和次要终点上均实现统计学显著改善，并展现良好的耐受性。▲Denifanstat临床3期试验结果摘要（图片来源：参考资料[1]）总缓解率超80%！核药获FDA突破性疗法认定Cellectar Biosciences今日宣布，其创新放射性偶联药物iopofosine I 131获得美国FDA授予突破性疗法认定，用于治疗复发/难治性华氏巨球蛋白血症（r/r WM）。Iopofosine I 131是一种潜在“first-in-class”的磷脂醚放射偶联靶向药物，具备独特的癌症精准治疗机制。该认定主要基于2期CLOVER WaM研究的积极结果，数据显示，iopofosine I 131在r/r WM患者中的总缓解率（ORR）达83.6%，主要缓解率（MRR）为58.2%（95% CI：0.42–0.67），显著超出预设20%的主要终点。目前，Cellectar亦正寻求欧洲药品管理局（EMA）指导，以确定该项研究是否符合快速通道和有条件上市申请标准，相关答复预计于今年7月下旬公布。首款！拜耳小分子联合疗法再获FDA批准拜耳（Bayer）日前宣布，其口服雄激素受体抑制剂Nubeqa（darolutamide）获得美国FDA批准，用于治疗转移性去势敏感性前列腺癌（mCSPC）成人患者。根据新闻稿，Nubeqa为首个获批用于该适应症的雄激素受体抑制剂。此次批准主要基于3期ARANOTE关键试验的积极数据。该试验共纳入669名mCSPC患者，按2：1比例随机分配接受Nubeqa或安慰剂联合雄激素剥夺致力（ADT）。结果显示，Nubeqa联合ADT将影像学进展或死亡风险显著降低46%（HR=0.54；95% CI：0.41–0.71；p<0.0001），相较于安慰剂联合ADT组具有统计学显著优势。此外，疗效在高肿瘤负荷与低肿瘤负荷等预设亚组中表现一致。Nubeqa的安全性结果与既往已建立的安全特征亦保持一致。参考资料：[1] Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis. Retrieved June 4, 2025 from https://www.globenewswire.com/news-release/2025/06/04/3093353/0/en/Sagimet-Biosciences-Announces-Positive-Phase-3-Results-for-Denifanstat-for-the-Treatment-of-Moderate-to-Severe-Acne-from-Partner-Ascletis.html[2] Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM). Retrieved June 4, 2025 from https://www.globenewswire.com/news-release/2025/06/04/3093528/29076/en/Cellectar-Granted-U-S-FDA-Breakthrough-Therapy-Designation-for-Iopofosine-I-131-in-Waldenstrom-Macroglobulinemia-WM.html[3] U.S. FDA Approves NUBEQA® (darolutamide) to Treat Patients with Metastatic Castration-Sensitive Prostate Cancer. Retrieved June 4, 2025 from https://www.businesswire.com/news/home/20250603153384/en/U.S.-FDA-Approves-NUBEQA-darolutamide-to-Treat-Patients-with-Metastatic-Castration-Sensitive-Prostate-Cancer免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

突破性疗法临床3期临床结果

2025-06-04

·investor.cellectar.com

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)

Designation Supported by CLOVER WaM Phase 2 Study Data Which Reported an 83.6% Overall Response Rate (ORR) Seeking Guidance from EMA to Determine if CLOVER WaM Phase 2 Data Meets Criteria to Apply for Fast-Track, Conditional Marketing Authorization, Answer Expected Late July FLORHAM PARK, N.J., June 04, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for iopofosine I 131, a potential first-in-class, novel cancer targeting agent utilizing a phospholipid ether as a radioconjugate monotherapy, for the treatment of relapsed/refractory Waldenstrom macroglobulinemia (r/r WM). WM is the dominant subtype of lymphoplasmacytic lymphoma and remains incurable with available therapies according to the International Waldenstrom’s Macroglobulinemia Foundation. Approved WM treatment options are limited, underscoring the need for new therapies with novel mechanisms of action. “The FDA’s Breakthrough Therapy Designation underscores the potential of iopofosine I 131 as it may offer substantial improvement on at least one clinically significant endpoint over available therapies to address the substantial unmet medical need in this life-threatening cancer,” said James Caruso, president and chief executive officer of Cellectar. “With robust clinical data, a favorable safety profile, expedited review designations in the United States and Europe and a compelling commercial market potential, we believe iopofosine I 131 represents an attractive candidate for potential collaborations or partners seeking impactful innovation and accelerated development pathways.” Data from the Phase 2 CLOVER WaM study (NCT02952508), including the overall response rate (ORR) of 83.6% and a major response rate (MRR) of 58.2% (95% CI, 0.42 to 0.67), which exceeded the agreed-upon primary endpoint of a 20% MRR, were presented as a podium presentation during the 66th Annual American Society of Hematology Conference in December 2024 by Sikander Ailawadhi, M.D., Professor of Medicine, Mayo Clinic. As previously announced, the FDA also granted iopofosine I 131 Fast Track Designation and Orphan Drug Designation. The European Medicines Agency (EMA) granted Orphan Drug Designation to iopofosine I 131 for treatment of r/r WM, as well as PRIME Designation for WM. Separately, the company announced that it has provided the EMA with a data package that includes extensive supportive preclinical, regulatory and manufacturing data, as well as safety and efficacy data from the CLOVER WaM Phase 2b clinical trial. The EMA will review the package to determine whether there is enough clinical evidence to address the required criteria for Cellectar to apply for a fast-track, conditional marketing authorization approval. In late July 2025 the company expects a recommendation from the EMA on whether Cellectar should file a Medical Authorization Application (MAA). About Breakthrough Therapy Designation Breakthrough Therapy Designation is an FDA program intended to expedite the development and review of medicines for serious or life-threatening diseases with preliminary clinical evidence that the investigational therapy may offer substantial improvement on at least one clinically significant endpoint over available therapies. The designation provides increased interactions with the FDA and supports the possibility of receiving a six-month priority review of a New Drug Application. About Cellectar Biosciences, Inc. Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s product pipeline includes: iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope); CLR 121225, an actinium-225 based program being targeted to several solid tumors with significant unmet need, such as pancreatic cancer; and CLR 121125, an iodine-125 Auger-emitting program targeted in other solid tumors, such as triple negative breast, lung and colorectal, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. In addition, iopofosine I 131 has been studied in Phase 2b trials for relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma, and the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has also granted iopofosine I 131 six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications. For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: X, LinkedIn, and Facebook. Forward Looking Statements Disclaimer This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to identify suitable collaborators, partners, licensees or purchasers for our product candidates and, if we are able to do so, to enter into binding agreements with regard to any of the foregoing, or to raise additional capital to support our operations, or our ability to fund our operations if we are unsuccessful with any of the foregoing. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2024, and our Form 10-Q for the quarter ended March 31, 2025. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements. INVESTORS: Anne Marie Fields Precision AQ 212-362-1200 annemarie.fields@precisionaq.com Released June 4, 2025

快速通道临床2期临床结果孤儿药ASH会议

100 项与 Iopofosine I-131 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15244

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
巨球蛋白血症	临床3期	美国	Cellectar Biosciences, Inc.	-
慢性淋巴细胞白血病	临床2期	美国	Cellectar Biosciences, Inc.	2017-07-26
慢性淋巴细胞白血病	临床2期	澳大利亚	Cellectar Biosciences, Inc.	2017-07-26
慢性淋巴细胞白血病	临床2期	巴西	Cellectar Biosciences, Inc.	2017-07-26
慢性淋巴细胞白血病	临床2期	捷克	Cellectar Biosciences, Inc.	2017-07-26
慢性淋巴细胞白血病	临床2期	芬兰	Cellectar Biosciences, Inc.	2017-07-26
慢性淋巴细胞白血病	临床2期	法国	Cellectar Biosciences, Inc.	2017-07-26
慢性淋巴细胞白血病	临床2期	希腊	Cellectar Biosciences, Inc.	2017-07-26
慢性淋巴细胞白血病	临床2期	以色列	Cellectar Biosciences, Inc.	2017-07-26
慢性淋巴细胞白血病	临床2期	西班牙	Cellectar Biosciences, Inc.	2017-07-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02952508 (ASH2024) 人工标引	临床2期	巨球蛋白血症三线	65	Iopofosine I 131 15 mCi/m2	齋衊鹹糧鏇蓋鹹窪願簾(觸淵襯餘夢構遞顧鏇膚) = occurred in 1 patient due to bacterial sepsis 觸簾繭壓餘壓衊夢製膚 (艱願範醖膚壓製夢鏇膚 ) 更多	积极	2024-12-09
NCT02952508 (CLOVER-WaM, Corporate Publications) 人工标引	临床2期	巨球蛋白血症	50	Iopofosine I 131	鑰廠構繭築憲鏇繭醖襯(糧範廠遞鏇鬱願觸窪遞) = 製鬱廠鹽積壓繭鏇觸蓋壓膚顧憲糧廠蓋選獵築 (艱齋選獵獵鑰觸憲衊鏇, 44.5 ~ 75.8) 达到更多	积极	2024-01-08
NCT02952508 (CLOVER-1, Literature) 人工标引	临床2期	复发性多发性骨髓瘤末线	7	CLR-131+dexamethasone (total dose ≥60 mCi)	遞繭艱遞顧築糧願鏇壓(製壓糧壓遞襯淵鹽醖憲) = 遞膚襯鹹醖繭網壓鏇壓艱餘構醖餘顧壓鬱網醖 (選簾醖獵網襯鏇襯選構 ) 更多	积极	2022-09-06
NCT02952508 (CLOVER-1, Literature) 人工标引	临床2期	复发性多发性骨髓瘤末线	7	CLR-131+dexamethasone (total dose <60 mCi)	-	积极	2022-09-06
NCT02952508 (CLOVER-1, ASCO2021)	临床2期	淋巴浆细胞性淋巴瘤 \| 套细胞淋巴瘤 \| 慢性淋巴细胞白血病 ... 更多	6	CLR 131	壓鏇餘鑰鹽顧蓋廠願構(壓顧憲襯顧繭鬱醖醖遞) = anaemia (66%) 膚積顧窪鏇願願餘蓋艱 (糧鑰鏇繭選構積構膚積 ) 更多	-	2021-05-28
NCT02952508 (ESMO2019) 人工标引	临床2期	复发性弥漫性大B细胞淋巴瘤	6	CLR-131	齋糧醖憲憲淵壓範齋淵(膚簾膚齋鹽襯夢構鏇齋) = 壓積構醖積製窪遞鹽鹹獵襯遞積蓋餘構艱憲衊 (鏇鑰窪餘艱鏇餘夢製鹹 ) 更多	积极	2019-09-28
AACR2018	临床2期	-	-	Fractionated injections of CLR 131	構簾廠築襯齋網醖鬱蓋(鹽顧夢醖遞鑰壓窪鹽鹽) = 廠選觸鹽艱觸餘衊簾齋鑰壓獵鑰醖窪繭淵鹽淵 (憲壓構範遞齋網範窪繭 )	-	2018-07-01
AACR2018	临床2期	-	-	Standard dosing of bortezomid	構簾廠築襯齋網醖鬱蓋(鹽顧夢醖遞鑰壓窪鹽鹽) = 襯衊蓋淵積齋廠範醖獵鑰壓獵鑰醖窪繭淵鹽淵 (憲壓構範遞齋網範窪繭 )	-	2018-07-01
NCT02278315 (ASH 12016 \| ASH 22016) 人工标引	临床1期	多发性骨髓瘤	8	dexamethasone+I-131-CLR1404	鹹壓蓋顧鬱齋窪顧膚繭(簾艱選衊遞膚蓋選鬱廠) = 夢鑰範簾衊廠積積顧範構繭築願窪顧觸選餘獵 (鑰廠範壓餘壓蓋獵鑰遞 )	积极	2016-12-02
NCT02278315 (ASH 12016 \| ASH 22016) 人工标引	临床1期	多发性骨髓瘤	8	dexamethasone+I-131-CLR1404	簾鹹鏇構繭廠窪獵積艱(膚醖顧觸鏇齋鹽構襯願) = 窪遞淵簾醖鬱遞簾壓齋淵網鹽願鹹顧窪觸鹽鑰 (餘齋範膚鑰廠觸鹹積顧 ) 更多	积极	2016-12-02
NCT00925275 (Pubmed \| PLoS One)	临床1期	晚期恶性实体瘤	8	131I-CLR1404	鹹鏇構衊蓋壓襯醖簾糧(鹽襯積獵遞積襯觸製廠) = 繭鬱鏇齋築夢築齋製齋遞衊壓範鬱鏇範齋鏇製 (繭構鬱構觸淵鏇蓋繭構 ) 更多	-	2014-11-17
NCT01495663 (ASCO2014)	临床1期	HR阳性/HER2低表达实体瘤	12	Phospholipid ether [<sup>131</sup>I]-CLR1404	獵糧夢膚築齋壓夢築壓(網醖製襯獵鹽齋襯繭網) = 範憲顧築餘糧範簾遞夢鏇構獵獵鬱範顧淵醖願 (憲簾糧廠夢積齋窪網艱 )	-	2014-05-20
AACR2013	N/A	头颈部鳞状细胞癌	-	131I-CLR1404	鏇襯鹹窪積網築餘築衊(遞窪獵網鑰窪積齋衊觸) = 膚廠憲鏇鑰積鹹廠衊齋積糧齋製醖蓋顧選鏇鹽 (糧齋齋積簾艱廠廠蓋鏇 ) 更多	-	2013-04-15